COVID-19 Health Evidence Summary No.101 by Millington, Kerry & Reddin, Samantha
    
 
 Evidence Summary 
y 
 
COVID-19  
Health Evidence Summary No.101 
Kerry Millington & Samantha Reddin 
Liverpool School of Tropical Medicine (LSTM) & Institute of Development Studies 
09 November 2020  
 
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
02.11.2020 SARS-CoV-2 
seroprevalence 
and 
transmission 
risk factors 
among high-
risk close 
contacts: a 
retrospective 
cohort study 
The Lancet 
Infectious 
Diseases | 
Article 
• Extensive contact 
tracing by MoH in 
Singapore for every 
diagnosed COVID-19 
case, legally enforced 
quarantine and 
intensive health 
surveillance of close 
contacts provided an 
opportunity to 
determine 
asymptomatic attack 
rates and SARS-CoV-
2 transmission risk 
factors among 
community close 
contacts of patients 
with COVID-19 
• Retrospective cohort 
study of all close 
contacts of confirmed 
COVID-19 cases in 
Singapore, identified 
between 23 Jan to 3 
Apr 2020 
• Risk factor analysis 
identified longer 
duration of verbal 
interaction and 
sharing a bedroom as 
Transmission, 
risk factors, 
contacts, 
household, 
non-
household 
 
 
independent exposure 
risk factors of SARS-
CoV-2 transmission to 
household close 
contacts 
• For non-household 
contacts risk factor 
analysis identified 
longer duration of 
verbal interaction, 
sharing a vehicle and 
having contact with 
more than one index 
case 
• Indirect contact, meal-
sharing and lavatory 
co-usage were no 
independently 
associated with 
SARS-CoV-2 
transmission in both 
household and non-
household contacts 
• Targeted community 
measures should 
include physical 
distancing and 
minimising verbal 
interactions 
• Routine testing of 
close contacts, 
regardless of 
symptoms, will reduce 
missed diagnoses 
with priority given to 
household contacts 
who are at high risk of 
SARS-CoV-2 
transmission 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
Nov 2020 The association 
of PPE 
availability, 
training and 
practices with 
COVID-19 
sero-
Disaster 
Medicine and 
Public Health 
Preparedness | 
Article 
• Univariate 
analysis of a 
cross-sectional 
study of 133 
nurses and 
paramedics 
found PPE 
availability, 
training and 
PPE availability, 
training, 
practice, 
frontline 
workers, 
seroprevelance 
 
 
prevalence in 
nurses and 
paramedics in 
tertiary care 
hospitals of 
Peshawar, 
Pakistan 
practices on 
COVID-19 
reduced sero-
prevalence 
among nurses 
and paramedics 
in teaching 
hospitals of 
Peshawar, 
Pakistan 
Therapeutics 
Publicatio
n date 
Title/URL Journal/Articl
e type 
Summary             Keywords 
05.11.202
0 
Remdesivir for the 
treatment of 
COVID-19 – final 
report 
NEJM | 
Article 
• Double-blind, 
randomised, 
placebo-
controlled trial of 
intravenous 
remdesivir in 
adults who were 
hospitalised with 
C19 and have 
evidence of lower 
respiratory tract 
infection found 
remdesivir as 
beneficial in the 
treatment of 
Covid-19 – 
consistent with 
the preliminary 
report 
• 10 day course of 
remdesivir was 
superior to 
placebo in 
shortening the 
time to recovery 
in adults who 
were hospitalised 
with C19 and 
have evidence of 
lower respiratory 
tract infection 
remdesivir 
05.11.202
0 
Remdesivir for 5 
or 10 days in 
patients with 
severe Covid-19 
NEJM | 
Article 
• Randomised, 
open-label, phase 
3 trial of 397 
hospitalised 
patients with 
severe Covid-19 
not requiring 
remdesivir 
 
 
mechanical 
ventilation 
• No significant 
difference was 
found between a 
5-day course and 
a 10-day course 
of remdesivir 
• With no placebo 
control, the 
magnitude of 
benefit cannot be 
determined 
05.11.202
0 
Effect of pre-
exposure use of 
hydroxychloroquin
e on COVID-19 
mortality: a 
population-based 
cohort study in 
patients with 
rheumatoid 
arthritis or 
systemic lupus 
erythematosus 
using the 
OpenSAFELY 
platform 
The Lancet 
Rheumatolog
y | Article 
• Observational, 
population-based 
study of 194,637 
people with 
rheumatoid 
arthritis or 
systemic lupus 
erythematosus of 
which 30,569 
(15.7%) received 
two or more 
prescriptions of 
hydroxychloroqui
ne 
• No evidence was 
found of any 
protective benefit 
of use of 
hydroxychloroqui
ne for prevention 
of COVID-19 
mortality in a 
general 
population 
• Authors suggest 
that randomised 
trials investigating 
pre-exposure 
prophylactic use 
of 
hydroxychloroqui
ne for prevention 
of severe 
outcomes from 
C19 are 
warranted 
hydroxychloroquin
e 
 
 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
   
• No new articles found (Refer 
to Comments, Editorials, 
Opinions, Blogs, News 
Section below for press 
release on Pfizer vaccine) 
 
Indirect impact of COVID-19 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
05.11.2020 Interventions 
to support 
the resilience 
and mental 
health of 
frontline 
health and 
social care 
professionals 
during and 
after a 
disease 
outbreak, 
epidemic or 
pandemic: a 
mixed 
methods 
systematic 
review 
Cochrane | 
Systematic 
Review 
• The two objectives of this 
SR were (1) how 
successfully any 
interventions improved 
frontline health 
professionals’ resilience 
or mental well-being and 
(2) what were the 
facilitators and barriers to 
delivery of these 
interventions 
• 16 relevant studies were 
found from different 
disease outbreaks (2 
SARS, 9 Ebola, 1 MERS, 
4 COVID-19) 
• No evidence was found 
on how well different 
strategies work at 
supporting the resilience 
and mental well-being of 
frontline workers. Limited 
evidence on facilitators of 
successful delivery. 
• Research to determine 
the effectiveness of 
interventions is a high 
priority with COVID-19 
offering a unique 
opportunity for robust 
evaluations of 
interventions   
Resilience, 
mental 
health, 
frontline 
workers 
 
 
Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
09.11.2020 Pfizer and BioNTech announce 
vaccine candidate against 
COVID-19 achieved success in 
first interim analysis from 
phase 3 study 
Pfizer | News 
• First interim efficacy analysis from 
phase 3 COVID-19 vaccine trial 
• Analysis evaluated 94 confirmed 
cases of COVID-19 in trial 
participants (trial will continue to final 
analysis at 164 confirmed cases) 
• Study enrolled 43,538 participants 
from six countries with 42% having 
diverse backgrounds 
• Effective in preventing more than 
90% of people from getting COVID-
19 (7 days after second dose) 
• No serious safety concerns have 
been observed so far; safety and 
additional efficacy data continue to 
be collected  
• The RNA-based vaccine requires 
two doses three weeks apart and its 
true efficacy over a longer period of 
time remains to be evaluated 
• There are logistical challenges as the 
vaccine has to be kept in ultra-cold 
storage at below minus 80oC 
07.11.2020 Strategy, coordinated 
implementation, and 
sustainable financing needed 
for COVID-19 innovations 
The Lancet | Comment 
07.11.2020 COVID-19 in Latin America: a 
humanitarian crisis 
The Lancet | Editorial 
06.11.2020 Public health during the 
pandemic in India 
Science | Perspective 
05.11.2020 The urgent need for a global 
commitment to protect 
healthcare workers 
BMJ Global Health | Commentary 
 
 
05.11.2020 Emergency use authorisation 
for COVID-19 vaccines: 
lessons from Ebola 
The Lancet | Comment 
05.11.2020 What could fair allocation of an 
efficacious COVID-19 vaccine 
look like in South Africa?  
The Lancet Global Health | Comment 
05.11.2020 Sex differences in COVID-19 
case fatality: do we know 
enough? 
The Lancet Global Health | Comment 
05.11.2020 Use first-ever “Finance in 
Common Summit” to propel 
global action for COVID-19 
recovery 
CGD | Blog 
04.11.2020 The BMJ Interview: Chris 
Whitty, England’s chief medical 
officer, on covid-19 
BMJ | Feature 
02.11.2020 Bridging the gap between need 
and innovation: the case of 
vaccines 
CGD | Blog 
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 Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence 
& policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps WHO Africa Ghana COVID-NMA WHO   FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard African 
Arguments 
Indonesia EPPI Centre WHO International 
Clinical Trials 
Registry Platform 
(ICTRP) 
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre 
LSHTM 
Johns Hopkins 
University 
European 
CDC 
Nigeria CDC Norwegian 
Institute of 
Public Health 
Cytel  Serology-
based tests for 
COVID-19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF   Sierra Leone  Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
 
 
Our World in 
Data 
  Singapore  Our World in 
Data: C19 Policy 
responses 
COVID-evidence       
Global 5050   UK  IFPRI COVID-
19 Policy 
Response Portal 
Cochrane       
CEBM, 
University of 
Oxford 
  US  COVID-19 
Primer 
Clinicaltrials.gov       
Humanitarian 
Data Exchange 
     NIH LitCovid  UKCDR       
Information is 
Beautiful 
     WHO COVID-
19 Database 
        
LSHTM               
HealthMap 
(cases) 
              
The Commons 
Project 
              
 
 
SeroTracker               
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C19 Resource Hubs 
 Global  Regional 
& Country 
Academi
c 
journals 
& 
Publisher
s 
Institutes/Centres/Funders/
Other 
Health 
Topics 
  Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin 
of the 
WHO 
ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambrid
ge 
Universit
y Press 
ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell 
Press 
Johns Hopkins University RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochran
e  
Center for Global 
Development 
 Epidemic 
Preparedne
ss 
Innovations 
  Social 
Developm
ent Direct 
C19 blog 
series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID Repository     
 
 
UNOCHA OCHA 
Southern 
and 
Eastern 
Africa 
COVID-19 
Digest 
Health 
Policy 
and 
Planning  
Norwegian Institute of 
Public Health 
    
UNHCR  South 
African 
Governme
nt 
JAMA 
Network 
Oxford Centre for 
Evidence-based Medicine 
    
UNICEF   The 
Lancet 
 HEART     
UNESCO   medRxiv 
and 
bioRxiv 
(Preprint
s) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
Universit
y Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent Epidemics      
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer 
Nature 
      
 
 
Reliefweb   SSRN 
(Preprint
s)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events 
  
Date Title/URL Online 
learning/event 
Duration Lead 
19.11.2020 Looking at the 
pandemic with a 
gender lens 
Live Twitter 
conversation 
  SSHAP 
 
 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online courses Varies WHO 
Available 
now 
Standard 
precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
 
 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, 
Modelling and Policy 
Online learning 2 weeks | 
2 hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays 
at 1700 
CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online learning 3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
Online learning Multiple 
self-paced 
course 
WHO 
 
 
coronavirus disease 
outbreak 
25 May 
2020 
COVID-19: Tackling 
the Novel 
Coronavirus 
Online learning 3 weeks | 
4 hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online learning 3 weeks | 
3 hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online learning 5 weeks | 
1 hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online learning Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2020. 
